EUVIMEDEUVIMED entdecken
Crossref

Prognostic value of Day 14 measurable residual disease in acute myeloid leukemia treated with venetoclax and azacitidine

Jiaying Lian, Xianxu Zhuang, Ying Chen, Qingqing Lin, Renzhi Pei, Dong Chen, Shuangyue Li, Peipei Ye, Junjie Cao, Jiaojiao Yuan, Xiaowei Shi, Xuhui Liu und 1 weitere

Cancer · 2025

DOI: 10.1002/cncr.70053 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, 2025. Verfasst von Jiaying Lian und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The Affiliated People's Hospital of Ningbo University, Ningbo, Zhejiang, China. Hauptthemen laut MEDLINE: Neoplasm, Residual, Leukemia, Myeloid, Acute, Bridged Bicyclo Compounds, Heterocyclic, Sulfonamides. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: Zhejiang Provincial Medical and Health Science and Technology Project, Yinzhou District Social Development Project, Ningbo Medical Science and Technology Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Venetoclax (VEN) in combination with azacitidine (AZA) (VEN‐AZA) is used to treat acute myeloid leukemia (AML) in patients who are not candidates for intensive chemotherapy but research on prognostic factors remains limited.

Methods

Measurable residual disease (MRD) by multiparametric flow cytometry in AML is important but there is limited evidence of the clinical utility of monitoring MRD in patients treated with VEN‐AZA. Herein, a total of 75 patients newly diagnosed with AML treated with VEN‐AZA were retrospectively analyzed to examine the role and timing of MRD to predict survival. MRD enabled the categorization of patients into two groups: Day 14 MRD, >1% (MRD 14‐pos ); and Day 14 MRD, ≤1% (MRD 14‐neg ).

Results

Of the 75 patients, 31 (41.3%) had MRD 14‐neg , whereas 30 (40.0%) had not achieved complete remission (CR) after induction. MRD 14‐neg was associated with improved overall survival (OS) ( p = .024) and event‐free survival (EFS) ( p = .044). In addition, MRD 14‐neg ( p = .002 for both OS and EFS), CSF3R negative ( CSF3R neg ) ( p < .001 for both OS and EFS), and transplantation ( p = .005 for OS; p = .007 for EFS) were associated with improved survival outcomes. Further subgroup analysis revealed that MRD 14‐pos patients who underwent transplantation showed a trend toward longer OS and EFS ( p < .001 for both).

Conclusions

Results in the MRD 14‐neg group were better than in the MRD 14‐pos group, and the prognosis for patients with AML was better when there was CSF3R neg and transplantation. Additionally, for patients with AML with MRD 14‐pos , consolidation with transplantation may increase survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplasm, ResidualLeukemia, Myeloid, AcuteBridged Bicyclo Compounds, HeterocyclicSulfonamidesAzacitidineAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMalePrognosisMiddle AgedAgedRetrospective StudiesAdultYoung AdultAged, 80 and overRemission Induction

Stichwörter der Autor:innen

CSF3Racute myeloid leukemiaazacitidinemeasurable residual disease (MRD)transplantationvenetoclax

Substanzen

venetoclaxBridged Bicyclo Compounds, HeterocyclicSulfonamidesAzacitidine

Autor:innen und Institutionen

  • Department of Hematology, The Affiliated People's Hospital of Ningbo University, Ningbo, Zhejiang, China.
  • Institute of Hematology, Ningbo University, Ningbo, Zhejiang, China.

ORCID-Profile: Ying Lu

Förderung

  • Zhejiang Provincial Medical and Health Science and Technology Project
  • Yinzhou District Social Development Project
  • Ningbo Medical Science and Technology Project

Zitieren

APA

Lian, J., Zhuang, X., Chen, Y., Lin, Q., Pei, R., Chen, D., Li, S., Ye, P., Cao, J., Yuan, J., Shi, X., Liu, X., & Lu, Y. (2025). Prognostic value of Day 14 measurable residual disease in acute myeloid leukemia treated with venetoclax and azacitidine. Cancer. https://doi.org/10.1002/cncr.70053

Vancouver

Lian J, Zhuang X, Chen Y, Lin Q, Pei R, Chen D, et al. Prognostic value of Day 14 measurable residual disease in acute myeloid leukemia treated with venetoclax and azacitidine. Cancer. 2025. doi:10.1002/cncr.70053

BibTeX
@article{Lian2025,
  author = {Lian, Jiaying and Zhuang, Xianxu and Chen, Ying and Lin, Qingqing and Pei, Renzhi and Chen, Dong and Li, Shuangyue and Ye, Peipei and Cao, Junjie and Yuan, Jiaojiao and Shi, Xiaowei and Liu, Xuhui and Lu, Ying},
  title = {Prognostic value of Day 14 measurable residual disease in acute myeloid leukemia treated with venetoclax and azacitidine},
  journal = {Cancer},
  year = {2025},
  doi = {10.1002/cncr.70053}
}
Kostenlos starten →